Table 2. Sex-disparate pathway enrichment. Selection of pathways significantly enriched in tumors of one sex but not the other.
| Pathway | Female p-value | Male p-value | Cancer |
|---|---|---|---|
| EIF2 Signaling | Non-significant | 2.63E-06 | HNSC |
| Tight Junction Signaling | Non-significant | 1.07E-05 | HNSC |
| Mitochondrial Dysfunction | Non-significant | 1.26E-05 | HNSC |
| LPS/IL-1 Mediated Inhibition of RXR Function | Non-significant | 1.58E-05 | HNSC |
| Activation of IRF by Cytosolic Pattern Recognition Receptors | 0.00112 | Non-significant | HNSC |
| Crosstalk between Dendritic Cells and Natural Killer Cells | 0.0239 | Non-significant | HNSC |
| Coagulation System | Non-significant | 0.000257 | KICH |
| Acute Phase Response Signaling | Non-significant | 0.00049 | KICH |
| Fatty Acid Î2-oxidation I | Non-significant | 1.78E-05 | KIRC |
| Ketogenesis | Non-significant | 1.48E-04 | KIRC |
| Valine Degradation I | Non-significant | 3.3E-04 | KIRC |
| LXR/RXR Activation | Non-significant | 5.01E-13 | LIHC |
| FXR/RXR Activation | Non-significant | 2.00E-11 | LIHC |
| LPS/IL-1 Mediated Inhibition of RXR Function | Non-significant | 7.94E-08 | LIHC |
| Coagulation System | Non-significant | 4.90E-07 | LIHC |
| Valine Degradation I | Non-significant | 1.15E-06 | LIHC |
| Sonic Hedgehog Signaling | 0.0468 | Non-significant | LIHC |
| Axonal Guidance Signaling | Non-significant | 9.33E-05 | LUAD |
| Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis | Non-significant | 1.02E-04 | LUAD |
| IL-8 Signaling | Non-significant | 1.62E-04 | LUAD |
| EIF2 Signaling | 9.12E-05 | Non-significant | LUAD |